| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2005
|
2.47
|
|
2
|
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.
|
J Clin Invest
|
2013
|
2.11
|
|
3
|
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.
|
J Clin Oncol
|
2012
|
2.02
|
|
4
|
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
|
Clin Cancer Res
|
2008
|
1.99
|
|
5
|
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
|
J Clin Invest
|
2014
|
1.81
|
|
6
|
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
|
J Clin Oncol
|
2008
|
1.80
|
|
7
|
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2006
|
1.64
|
|
8
|
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.
|
Ann Surg Oncol
|
2012
|
1.56
|
|
9
|
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2009
|
1.53
|
|
10
|
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
|
Cancer Discov
|
2013
|
1.52
|
|
11
|
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
|
Cell Rep
|
2013
|
1.43
|
|
12
|
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.
|
Clin Cancer Res
|
2009
|
1.30
|
|
13
|
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2007
|
1.28
|
|
14
|
Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
|
J Clin Oncol
|
2003
|
1.28
|
|
15
|
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
|
J Am Acad Dermatol
|
2012
|
1.27
|
|
16
|
Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?
|
J Nucl Med
|
2004
|
1.19
|
|
17
|
P gene as an inherited biomarker of human eye color.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
1.15
|
|
18
|
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
|
J Clin Oncol
|
2012
|
1.09
|
|
19
|
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.
|
Cancer Res
|
2007
|
1.08
|
|
20
|
Multiple primary melanoma revisited.
|
Cancer
|
2002
|
1.02
|
|
21
|
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.
|
Clin Cancer Res
|
2009
|
1.00
|
|
22
|
Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.94
|
|
23
|
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
|
J Clin Invest
|
2016
|
0.93
|
|
24
|
Local immune response predicts survival in patients with thick (t4) melanomas.
|
Ann Surg Oncol
|
2013
|
0.86
|
|
25
|
Retransplantation of a cardiac allograft inadvertently harvested from a donor with metastatic melanoma.
|
Transplantation
|
2003
|
0.80
|
|
26
|
Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection.
|
Transpl Int
|
2010
|
0.79
|
|
27
|
Drug targeting of oncogenic pathways in melanoma.
|
Hematol Oncol Clin North Am
|
2009
|
0.79
|
|
28
|
Effectively targeting BRAF in melanoma: a formidable challenge.
|
Pigment Cell Melanoma Res
|
2008
|
0.79
|
|
29
|
Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma.
|
J Health Psychol
|
2003
|
0.78
|
|
30
|
Physician and stakeholder perceptions of conflict of interest policies in oncology.
|
J Clin Oncol
|
2013
|
0.77
|
|
31
|
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.
|
J Interferon Cytokine Res
|
2014
|
0.76
|
|
32
|
ACUTE EXUDATIVE PARANEOPLASTIC POLYMORPHOUS VITELLIFORM MACULOPATHY DURING VEMURAFENIB AND PEMBROLIZUMAB TREATMENT FOR METASTATIC MELANOMA.
|
Retin Cases Brief Rep
|
2017
|
0.75
|